With Swiss pickup, Pfizer adds CMV candidate to growing vaccines unit

After 2014's growth spurt, Pfizer's ($PFE) vaccines unit hasn't finished expanding. The pharma giant grabbed privately held Swiss company Redvax for an undisclosed sum, adding a preclinical human cytomegalovirus (CMV) vaccine candidate, and a tech platform and IP related to a second, undisclosed vaccine program. But Pfizer will need to keep bulking up if it wants to stay competitive with its Big Pharma peers. It currently trails Merck ($MRK), Sanofi ($SNY) and GlaxoSmithKline ($GSK) in the global vaccines market, and with Glaxo's deal for Novartis' ($NVS) vaccines unit, that top 3 will only be getting more difficult to crack. More

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.